Middle-market private equity shop Linden Capital Partners has promoted Bill Drehkoff to partner and Todd Van Horn to principal, the firm announced. The Chicago-based firm focuses on leveraged buyouts in the healthcare and life sciences industries, and has $575 million in assets under management.
Linden Capital Partners announced today the promotion of Bill Drehkoff to Partner and Todd Van Horn to Principal, effective immediately. Linden, a middle-market private equity firm focused on leveraged buyouts in the healthcare and life sciences industries, has $575 million in assets under management and is comprised of a team of 11 investment professionals and 8 operating executives with deep experience in Linden’s targeted sectors of healthcare.
Eric Larson, Managing Partner, noted: “Bill’s promotion formally recognizes his significant contributions to our team, our portfolio companies, and our culture.” Mr. Drehkoff re-joined the team at Linden in 2009 after beginning his principal investing career with the founders of Linden Capital Partners at First Chicago Equity Capital over 12 years ago. Mr. Drehkoff’s focus has been on developing platform investments in diagnostics, oral care, life sciences, and specialty distribution. He currently serves on the board of directors of Hycor BioMedical and SeraCare Life Sciences. Following his experience at First Chicago Equity Capital, Mr. Drehkoff earned an MBA with honors from the University of Chicago and was a Principal at The Boston Consulting Group.
Todd Van Horn joined Linden in 2008 and focuses on investments in the medical products, orthopedics, and laboratory services sectors. “Over the last four years, Todd has been a valuable team member and has developed deep sector expertise,” said Managing Partner Tony Davis. Prior to joining Linden, Mr. Van Horn was a Principal and founding member of Healthcare Investment Partners, a private equity partnership focused on healthcare products and related services companies. He began his career in the healthcare investment banking group at Credit Suisse First Boston. Mr. Van Horn currently serves on the board of directors of Strata Pathology Services and CORPAK MedSystems. Mr. Van Horn holds a Bachelor of Science in Molecular, Cell and Developmental Biology from the University of California, Los Angeles and an MBA from the Kellogg School of Management.
Brian Miller, Managing Partner, added: “Bill and Todd exemplify Linden’s core values especially our commitment to collaboration with our Operating Partners. We are thrilled to recognize their respective achievements and the ongoing value they bring to Linden.”
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is comprised of three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic corporate relationships. Linden invests in middle market companies across the healthcare spectrum, including medical products, healthcare services, and distribution.